Floatz logo

BARDOXOLONE METHYL ESTER

CKD Associated With Type 1 Diabetes

BiogenSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the CKD Associated With Type 1 Diabetes cohort.

Asset / SponsorPhaseRating
Folic Acid
Fuling Central Hospital of Chongqing City
Phase 2/3BB
Spironolactone
Hospital de Messejana Dr. Carlos Alberto Studart Gomes
Phase 4BB
VALSARTAN
Columbia University
Phase 4BB
Nifedipine
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase 3BB
Lisinopril
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase 3BB

View all 18 →

Same molecule, other indications

BARDOXOLONE METHYL ESTER is also rated in:

pulmonary hypertensionDormant
B
Indicative ·
57 / 100
View asset →
pulmonary arterial hypertensionDormant
B
Indicative ·
57 / 100
View asset →
interstitial lung diseaseDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →